The Biotech Recovery Is Here—But It’s “Selective.” Is Your Supply Chain Ready?
I. The Recovery Is Real—But It’s “Selective”
Halfway through 2026, global healthcare investment and financing has emerged from the “winter” shadows. But to declare a “bull market” based on these numbers alone would be to miss the deeper structural shifts behind this recovery.
This is not a “full reversal,” but a “selective recovery” . Capital is no longer spreading evenly like “sprinkling pepper”——it is highly concentrated on quality assets with true differentiation, global potential, and verifiable value.
For procurement decision-makers and R&D leads at drug discovery labs, what does this mean? In short: your upstream suppliers also need to match the pace of this “selective recovery”——with the flexibility to support early-stage target validation and the capacity to scale as programs advance toward the clinic.
II. What the Data Says
Start with BD deals. As of July 21, the total value of China‘s innovative drug License-out deals had reached **$109.9 billion**, across 140 transactions, with upfront payments of $5.9 billion. Total deal value has reached 79% of the full-year 2025 total, with upfront payments at 82% of the 2025 full-year. In the first half of 2026, Chinese companies claimed 8 of the top 10 global biopharma deals.
Now look at investment and financing. In the first half of 2026, the global innovative drug primary market recorded 505 financing events, raising $26.75 billion, up 58.5% year-over-year. China‘s healthcare primary market recorded 814 financing events, raising RMB 72.56 billion, up 41.7% year-over-year. Global pharma primary and secondary market financing grew 95% year-over-year, reaching approximately 75% of the full-year 2025 total.
The IPO market is also active. The Hong Kong IPO market raised HK$210 billion, a five-year first-half record. On July 23, Synvina’s STAR Market IPO registration was approved, targeting RMB 2.94 billion. On July 27, Lianya Pharma‘s ChiNext IPO registration became effective.
III. GLP-1 Momentum Continues, Supply Chain Demands Are Escalating
The GLP-1 space has also seen dense signals recently. On July 20, Wentai Pharmaceutical’s VCT220 NDA was accepted by the NMPA, making it the first domestic small-molecule GLP-1 receptor agonist to file for marketing approval. 52-week clinical data showed -12.4% weight loss in the 160 mg dose group.
On July 21–22, clinical trial applications for two GLP-1 oral weekly formulations——Innovent's IBI3042 and Gan & Lee's GZC8072——were accepted by the NMPA, with IBI3042 being the world's first small-molecule GLP-1 weekly formulation to enter clinical development. Domestic oral GLP-1 competition has now escalated from daily to weekly formulations.
From clinical development to commercialization, from daily to weekly dosing——every upgrade in the GLP-1 space drives demand for high-purity intermediates, chiral building blocks, and complex heterocyclic compounds to higher volumes and greater complexity.
IV. CXO Fundamentals Confirm: Upstream Supply Chains Are Benefiting
The ripple effects of the recovery are already visible in the upstream service sector. Since July, several CXO companies——including Pharmaron, Joinn Laboratories, and Medicilon——have released strong H1 2026 earnings pre-announcements. The CRO index rebounded 31.43% from June 8 to July 16.
Pharmaron's small-molecule CDMO new orders grew over 50% year-over-year. The bidding price for cynomolgus monkeys has risen from under RMB 100,000 to RMB 190,000 per animal——a visible indicator of preclinical CRO activity.
V. Beixinke Chem's Perspective
As a custom synthesis service provider based in Shanghai, specializing in inhibitor small molecules, heterocyclic intermediates, and chiral building blocks, Beixinke Chem is witnessing the real-world transmission of this “selective recovery.”
【 One real-world signal from our front line: since the beginning of 2026, we have seen a noticeable increase in inquiries for new product development. Compared to 2025, demand for custom synthesis from labs and research organizations is accelerating——with requirements that are more specific, more concrete, and more urgent. 】
We have observed that when the industry is at a low point, R&D organizations tend to scale back external collaborations and reduce custom synthesis investment. When the cycle turns, the first segment to recover is often early-stage R&D custom synthesis——because that is the link in the drug discovery chain that most requires external specialized support.
Our core capabilities cover the entire chain from retrosynthetic analysis to process scale-up: chiral construction, heterocyclic assembly, milligram-to-kilogram scale-up, and full HPLC/LC-MS/NMR analytical support. We have provided custom synthesis support to R&D labs and biotech companies both in China and internationally——across different scales and requirements.
If your R&D team is also tracking what this recovery means for your supply chain, we would welcome the conversation.